why choose us

First received: March 14, 2023

Clinical Trial: Efficacy of MT-601 in Patients With Relapsed/Refractory Lymphoma

Study Status: Completed

Recruit Status: RECRUITING

Condition: Non-Hodgkin Lymphoma, Adult

Study Type: INTERVENTIONAL


Official Title: A Phase 1 Study of Patient-Derived Multi-Tumor-Associated Antigen-Specific T Cells (MT-601) Administered to Patients With Relapsed or Refractory Non-Hodgkin Lymphoma (NHL [APOLLO])

Brief Summary: This study is a Phase 1multicenter study with a Dose Escalation and Dose Expansion evaluating safety and efficacy of MT-601 administration to patients with Relapsed or Refractory NHL.The dose administered is 200 x 10^6 cells (flat dosing).

Read more